DETERMINATION OF SOME PHARMACOKINETIC PROPERTIES OF ARTEMETHER-LUMEFANTRINE GRANULES IN ALBINO RATS

Aim and Objectives: Malaria is an infectious disease that is caused by plasmodium parasites which is rampant in Sahara Africa and children under 5 years of age are highly vulnerable to this infection by malaria. So the need for the formulation of dosage form for this population using naturally occurring excipients to replace imported ones being currently used by our local manufacturing industries in-order to formulate novel, readily available, affordable and effective antimalarial medicine for children. Methods: Using the local excipients and its hybrid, the formulated artemether-lumefantrine granules for oral suspension were administered to albino rats, blood samples were collected at predetermined time 0, 1.5, 3, 6, 9, 12, 15, 18, 21, and 24 h respectively and drug contents; artemether-lumefantrine were determined within the stipulated period. Results: Some pharmacokinetic parameters determined were; maximum concentration, Cmax, time to reach the maximum concentration, Tmax, half-life, t1/2, area under the curve, AUC, and mean residence time, MRT, which were for artemether-lumefantrine were 3.9, 3.4, μg/L; 3.2, 6.0 h; 12.5, 14 h; 75.8, 168.5 μg/L.h; 24, 24 h respectively, for the marketed artemether-lumefanthrine granules for oral suspension.4.1, 3.2 μg/L; 1.4, 3.0 h; 3.0, undefined h, 67.0, 65.7 μg/L. h; 18, 18 respectively for hybrid formulated artemether-lumefantrine granules for oral suspension and 3.1, 3.8 μg/L; 2.5, 12.5 h; 4.8, 15 h; 20.2, 281.6 μg/L .h; 18, 18 respectively for the extracted pectin formulated granules. Conclusion: Optimized formulated artemether-lumefantrine granules were superior to the marketed product in terms of pharmacokinetic values being closer to those of earlier workers. Peer Review History: Received 13 May 2024; Reviewed 16 July 2024; Accepted 22 August; Available online 15 September 2024 Academic Editor: Dr. Asia Selman Abdullah, Pharmacy institute, University of Basrah, Iraq, [email protected] Average Peer review marks at initial stage: 5.5/10 Average Peer review marks at publication stage: 7.0/10 Reviewers: Ahmad Najib, Universitas Muslim Indonesia, Makassar, Indonesia, [email protected] Dr. Sangeetha Arullappan, Universiti Tunku Abdul Rahman, Malaysia, [email protected]

Authors

Institutions

Publication Details

Journal
Universal Journal of Pharmaceutical Research
Published
2024-09-14
DOI
https://doi.org/10.22270/ujpr.v9i4.1163
Primary Topic
Natural Antidiabetic Agents Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

DETERMINATION OF SOME PHARMACOKINETIC PROPERTIES OF ARTEMETHER-LUMEFANTRINE GRANULES IN ALBINO RATS

Edwin Aboje Ubieko, Emmanuel A. Ubieko
Universal Journal of Pharmaceutical Research
Natural Antidiabetic Agents Studies
article

DETERMINATION OF SOME PHARMACOKINETIC PROPERTIES OF ARTEMETHER-LUMEFANTRINE GRANULES IN ALBINO RATS

Edwin Aboje Ubieko, Emmanuel A. Ubieko
article en

Abstract

Aim and Objectives: Malaria is an infectious disease that is caused by plasmodium parasites which is rampant in Sahara Africa and children under 5 years of age are highly vulnerable to this infection by malaria. So the need for the formulation of dosage form for this population using naturally occurring excipients to replace imported ones being currently used by our local manufacturing industries in-order to formulate novel, readily available, affordable and effective antimalarial medicine for children. Methods: Using the local excipients and its hybrid, the formulated artemether-lumefantrine granules for oral suspension were administered to albino rats, blood samples were collected at predetermined time 0, 1.5, 3, 6, 9, 12, 15, 18, 21, and 24 h respectively and drug contents; artemether-lumefantrine were determined within the stipulated period. Results: Some pharmacokinetic parameters determined were; maximum concentration, Cmax, time to reach the maximum concentration, Tmax, half-life, t1/2, area under the curve, AUC, and mean residence time, MRT, which were for artemether-lumefantrine were 3.9, 3.4, μg/L; 3.2, 6.0 h; 12.5, 14 h; 75.8, 168.5 μg/L.h; 24, 24 h respectively, for the marketed artemether-lumefanthrine granules for oral suspension.4.1, 3.2 μg/L; 1.4, 3.0 h; 3.0, undefined h, 67.0, 65.7 μg/L. h; 18, 18 respectively for hybrid formulated artemether-lumefantrine granules for oral suspension and 3.1, 3.8 μg/L; 2.5, 12.5 h; 4.8, 15 h; 20.2, 281.6 μg/L .h; 18, 18 respectively for the extracted pectin formulated granules. Conclusion: Optimized formulated artemether-lumefantrine granules were superior to the marketed product in terms of pharmacokinetic values being closer to those of earlier workers. Peer Review History: Received 13 May 2024; Reviewed 16 July 2024; Accepted 22 August; Available online 15 September 2024 Academic Editor: Dr. Asia Selman Abdullah, Pharmacy institute, University of Basrah, Iraq, [email protected] Average Peer review marks at initial stage: 5.5/10 Average Peer review marks at publication stage: 7.0/10 Reviewers: Ahmad Najib, Universitas Muslim Indonesia, Makassar, Indonesia, [email protected] Dr. Sangeetha Arullappan, Universiti Tunku Abdul Rahman, Malaysia, [email protected]

Universal Journal of Pharmaceutical Research
University of Port Harcourt (NG)
Openalex Percentile: Top 76%
Natural Antidiabetic Agents Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.